AnaptysBio Inc
NASDAQ:ANAB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.55
40.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
AnaptysBio Inc
Wall Street
Price Targets
ANAB Price Targets Summary
AnaptysBio Inc
According to Wall Street analysts, the average 1-year price target for
ANAB
is 36.11 USD
with a low forecast of 19.19 USD and a high forecast of 59.85 USD.
ANAB Last Price Targets
AnaptysBio Inc
The latest public price target was made on Nov 6, 2024 by
David Risinger
from
Leerink Partners
,
who expects
ANAB
stock to
rise by 209%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
David Risinger
Leerink Partners
|
45
USD
Upside 209% |
1 month ago
Nov 6, 2024
|
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
StreetInsider
|
|
Emily Bodnar
H.C. Wainwright
|
52
USD
Upside 257% |
1 month ago
Nov 6, 2024
|
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
StreetInsider
|
Yatin Suneja
Guggenheim
|
90
USD
Upside 519% |
2 months ago
Oct 21, 2024
|
AnaptysBio (ANAB) PT Raised to $90 at Guggenheim
StreetInsider
|
Yasmeen Rahimi
Piper Sandler
|
80
USD
Upside 450% |
2 months ago
Oct 15, 2024
|
Piper Sandler Reiterates Overweight Rating on AnaptysBio (ANAB)
StreetInsider
|
|
David Risinger
New Street
|
35
USD
Upside 141% |
2 months ago
Oct 3, 2024
|
Leerink Partners Reiterates Outperform Rating on AnaptysBio (ANAB)
StreetInsider
|
Joon Lee
Truist Financial
|
30
USD
Upside 106% |
4 months ago
Aug 15, 2024
|
AnaptysBio price target raised to $30 from $20 at Truist
TheFly
|
|
David Risinger
Leerink Partners
|
47
USD
Upside 223% |
8 months ago
Apr 16, 2024
|
AnaptysBio initiated with an Outperform at Leerink
TheFly
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ANAB's stock price target?
Price Target
36.11
USD
According to Wall Street analysts, the average 1-year price target for
ANAB
is 36.11 USD
with a low forecast of 19.19 USD and a high forecast of 59.85 USD.
What is AnaptysBio Inc's Revenue forecast?
Projected CAGR
32%
For the last 8 years the
compound annual growth rate for
AnaptysBio Inc's revenue is
0%.
The projected
CAGR
for the next 4 years is
32%.
You don't have any saved screeners yet
